article thumbnail

COVID-19 Vaccine Safe for Children Who Had Previous MIS-C Diagnosis

Drug Topics

Patients with a history of multisystem inflammatory syndrome in children (MIS-C) completed a questionnaire about adverse reactions following COVID-19 vaccination, and no serious adverse events were recorded.

article thumbnail

Rare MIS-C Does Not Appear to Impact COVID-19 Vaccine Safety in Children

Pharmacy Times

Children who experienced COVID-19-induced multisystem inflammatory syndrome did not experience severe adverse reactions following COVID-19 vaccination.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel

pharmaphorum

Reviewers from the FDA have given their blessing to the Pfizer/BioNTech COVID-19 vaccine ahead of a key meeting tomorrow – but the regulator noted that there are still uncertainties about whether the shot can stop the disease from spreading. The post FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel appeared first on.

Vaccines 111
article thumbnail

Non-vaccine nasal spray could protect against COVID-19

pharmaphorum

The programme is still in the early stages of development, but if it works in trials would provide another approach to prevent transmission of SARS-CoV-2, the virus that causes COVID-19, alongside vaccines and prophylactic antibodies. The post Non-vaccine nasal spray could protect against COVID-19 appeared first on.

Vaccines 133
article thumbnail

mRNA vaccine trial shows efficiency in older adults with RSV

European Pharmaceutical Review

mRNA-1345 demonstrated vaccine efficacy (VE) of 83.7 percent in Moderna’s mRNA vaccine Phase III trial targeting respiratory syncytial virus (RSV) in older adults. ” Moderna’s mRNA vaccine – mRNA-1345. mRNA-1345 is an investigational RSV vaccine. Moderna launches two new mRNA vaccine programmes.

Vaccines 105
article thumbnail

Health Canada approves Novavax’s Covid-19 vaccine for adolescents

Pharmaceutical Technology

Health Canada has granted approval for a supplement to a New Drug Submission (sNDS) of Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted), Nuvaxovid (NVX-CoV2373), for use in adolescents aged 12 to 17 years. The trial is designed to analyse the safety and effectiveness of the vaccine.

Vaccines 105
article thumbnail

EC approves Novavax’s Covid-19 vaccine CMA expansion for adolescents

Pharmaceutical Technology

The European Commission (EC) has granted approval for the expanded conditional marketing authorization (CMA) of Novavax’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), in the European Union (EU) for adolescents of the age 12 to 17 years. A protein-based vaccine, NVX-CoV2373 is made from the genetic sequence of the SARS-CoV-2 virus’ first strain.

Vaccines 105